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Background: The TRIM5α protein is a principal restriction factor that contributes to an HIV-1 replication block in
rhesus macaque CD4+ T cells by preventing reverse transcription. HIV-1 restriction is induced in human CD4+ T cells
by expression of rhesus TRIM5α as well as those of other old world monkeys. While TRIM5α restriction has been
extensively studied in single-round infection assays, fewer studies have examined restriction after extended viral
replication.
Results: To examine TRIM5α restriction of replication, we studied the ability of TRIM5α proteins from African green
monkey (AgmTRIM5α) and gorilla (gorTRIM5α) to restrict HIV-1 and SIVmac239 replication. These xenogeneic TRIM5α
genes were transduced into human Jurkat-CCR5 cells (JR5), which were then exposed to HIV-1 or SIVmac239. In our
single-round infection assays, AgmTRIM5α showed a relatively modest 4- to 10-fold restriction of HIV-1 and
SIVmac239, while gorTRIM5α produced a 2- and 3-fold restriction of HIV-1 and SIVmac239, respectively, consistent with
the majority of previously published single-round studies. To assess the impact of these modest effects on infection,
we tested restriction in replication systems initiated with either cell-free or cell-to-cell challenges. AgmTRIM5α
powerfully restricted both HIV-1 and SIVmac239 replication 14 days after cell-free infection, with a ≥ 3-log effect.
Moreover, expression of AgmTRIM5α restricted HIV-1 and SIVmac239 replication by 2-logs when co-cultured with
infected JR5 cells for 12 days. In contrast, neither expression of gorTRIM5α nor rhesus TRIM5α induced significant
resistance when co-cultured with infected cells. Follow up experiments showed that the observed differences
between replication and infection were not due to assembly defects as xenogeneic TRIM5α expression had no
effect on either virion production or specific infectivity.
Conclusions: Our results indicate that AgmTRIM5α has a much greater effect on extended replication than on any
single infection event, suggesting that AgmTRIM5α restriction acts cumulatively, building up over many rounds of
replication. Furthermore, AgmTRIM5α was able to potently restrict both HIV-1 and SIV replication in a cell-to-cell
infection challenge. Thus, AgmTRIM5α is unique among the TRIM5α species tested to date, being able to restrict
even at the high multiplicities of infection presented by mixed culture with nonrestrictive infected cells.
Keywords: HIV, SIV, TRIM5α, Restriction factor, Cumulative restrictionBackground
Studying cellular resistance to HIV-1 infection mediated
by cellular proteins, i.e. resistance factors, is important
for the understanding of viral biology and identifying po-
tential opportunities for AIDS therapeutics [1-10]. These
cellular proteins interact with viral partners to block
various steps in the retroviral replication cycle, thereby
suppressing virus infection and spread [11]. The TRIM5α
restriction factor belongs to the very large tripartite motif* Correspondence: ottde@mail.nih.gov
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unless otherwise stated.(TRIM) family of proteins [12,13], and is a well-studied
HIV-1 resistance factor [14]. In the early 1990’s, a re-
sistance to HIV-1 infection of rhesus macaque cells was
observed, manifested as a post-entry block to reverse tran-
scription that mapped to a few viral proteins, most notably
Gag [15-17]. Over a decade later, the TRIM5α cytoplasmic
body protein, was identified as a principal restriction fac-
tor for HIV-1 in rhesus macaque CD4+ T cells which
binds the capsid protein (CA) in capsid cores after virus
entry, thereby, interfering with early reverse transcription
[18,19]. In many cases viral restriction in normally per-
missive cells can be produced by ectopic expression ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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producing a somewhat complicated pattern of restriction
in a variety of virus/TRIM5α pairings [18,20-26].
As with all TRIM family members [12,13], TRIM5α
contains a really interesting new gene (RING) finger
domain with an E3 ubiquitin ligase activity, a B-box zinc
finger, a coiled-coil domain as well as a fourth non-
canonical B30.2(SPRY) domain [12,13]. The basis for the
differential xenogeneic restricting capabilities of TRIM5α
proteins lies in the RING and B30.2(SPRY) domains.
The B30.2(SPRY) region binds capsid and is necessary,
but not sufficient for restriction [9,18,27-30]. A single
amino acid difference in the RING finger is critical for
the restriction of SIVmac by tantalus African green
monkey TRIM5α (AgmTRIM5α) [31,32], but not other
TRIM5α/virus combinations [18,29,33,34]. Thus, the
contributions of the RING domain across the different
TRIM5α/virus combinations are quite complicated and,
in some cases, unclear. Also, the exact nature of the
block is clouded by data supporting the possibility of
multiple mechanisms of interference with the post-entry in-
fection process that act between early reverse transcription
[18] and nuclear entry/integration of the cDNA [35,36].
TRIM5α restricts infection inside the cell by binding
the CA-coated capsid core structure soon after entry
[37]. The capsid core contains all of the elements needed
for infection, the genomic RNA bound by nucleocapsid
protein, reverse transcriptase, and integrase, all encased
in a highly structured conical CA protein shell poised to
carry out the infection process [38]. Current models
propose infection proceeding, post-entry, by the CA core
rearranging and partially uncoating in a controlled man-
ner at the appropriate time to allow for reverse tran-
scription. Therefore, CA-CA interactions in the capsid
core need to be finely balanced, strong enough to main-
tain core structure in virio, yet weak enough to appro-
priately uncoat during the infection process inside the
cell. Indeed, virion infectivity requires the correct conical
capsid core structure [39]: CA mutations that either
stabilize or destabilize the capsid core have drastic ef-
fects on infectivity, reflecting the fragile balance of core
stability [40].
The exact mechanism for TRIM5α restriction is not
completely understood, but it clearly involves TRIM5α
binding the CA shell in a highly cooperative manner,
which results in the proteins forming an ordered cage
around the core [41,42]. The current data supports two
models for the mechanism of TRIM5α restriction. In
one model, the TRIM5α cage disrupts the normal, pre-
sumably ordered, rearrangement and uncoating process,
thereby prematurely disintegrating the CA shell [35,43-45].
Alternatively, the RING finger E3 ubiquitin ligase activity
of TRIM5α could be ubiquitinated itself as well as CA after
complex formation, marking both TRIM5α and the CAcore for destruction by the proteasome [32,36]. Indeed,
TRIM5α and viral components are associated with cyto-
plasmic bodies that accumulate upon proteasome inhib-
ition [46], although CA ubiquitination by TRIM5α has not
yet been observed. It is important to note that these two
models are not mutually exclusive and there is strong evi-
dence that different TRIM5α/virus combinations could use
different mechanisms (please see references in [32,36,42]).
For instance, HIV-1 restriction by rhesus macaque TRIM5α
(rhTRIM5α) does not require the RING E3 ubiquitin ligase
activity [35], while this function is required for restriction
of SIVmac by AgmTRIM5α [32]. Finally, TRIM5α acts as a
pattern recognition receptor that senses TRIM5α-capsid
core complexes, which then activates innate immune
signaling [47]. While its exact contribution to restriction
is not clear, this induction of signaling is required for
TRIM5α restriction in some experimental contexts [47].
Normally, human TRIM5α restricts only a few retro-
viruses, being ineffective against HIV-1, SIVmac and
SIVAgm [22,24,25], although transduction of a mutant
human TRIM5α with an extended half-life can induce
HIV-1 restriction in human cells [10]. In contrast,
single-round infectivity assays with pseudotyped defec-
tive viruses or viral vectors have found that rhTRIM5α
strongly (>70- 95%) restricts HIV-1 infection, while Agm-
TRIM5α weakly (~60%) restricts SIVmac, with gorilla
TRIM5α (gorTRIM5α) having a stronger effect (~90%)
[22]. Despite a large body of infection experiments, only a
few studies have examined TRIM5α restriction using wild-
type viruses in cell-free replication assays [8,10,18,30,48,49].
TRIM5α restriction provides a potent block to HIV-1
infection of rhesus macaque CD4+ T cells that, along
with other resistance factors, make them essentially un-
able to support a spreading infection [17,23,48,50]. Be-
cause of this effect, xenogeneic expression of rhTRIM5α
by gene transfer has been proposed as a way to protect
human CD4+ T cells from HIV-1 [1,3-5]. Despite its
promise, preliminary work indicated that xenogeneic ex-
pression of rhTRIM5α protected primary human CD4+
T cells only under certain circumstances [48], most not-
ably when all of the cells expressed the restricting pro-
tein. rhTRIM5α failed to protect cells from HIV-1
exposure by cell-to-cell contact with infected cells with-
out rhTRIM5α [48]. To better investigate the basis for
TRIM5α restriction of replication and extend TRIM5α-
mediated restriction studies to the SIV/rhesus macaque
model system, we chose to examine two lesser-studied
TRIM5α proteins that were previously found to restrict
SIVmac, AgmTRIM5α and gorTRIM5α, for their ability
to restrict either HIV-1 or SIVmac239 replication in a hu-
man CD4+ T-cell line. Our results showed that, despite a
relatively weak effect against HIV-1 and SIVmac viruses
and pseudotyped vectors in short term and single-round
infection assays, AgmTRIM5α expression induced a high
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a human CD4+ T-cell line in both cell-free and cell-to-
cell challenge systems.
Results
To study TRIM5α restriction, we produced murine retro-
viral vectors that express N-terminally hemagglutinin epi-
tope (HA) tagged TRIM5α proteins from either tantalus
African green monkey (SMS-hAgmT) or gorilla (SMS-
hgorT) [21,22] along with the GFP and the puromycin
resistance genes. Because, N-terminal HA tags might
affect the function of TRIM5α [20], we also produced two
vectors (Babe-AgmT and Babe-gorT) that express native
TRIM5α proteins and the puromycin-resistance gene. JR5
cells (human Jurkat CD4+ T cells transduced with the
CCR5 gene) were transduced with pseudotyped vectors
and puromycin resistant cells were selected, producing the
hAgmT, hgorT, AgmT, and gorT cell lines. To measure
the expression of ecotopic TRIM5α in these JR5 cell lines,
we analyzed cell lysates by immunoblotting using the
quantitative two-color near infrared fluorescence (NIr) LI-
COR system with the 3F1-1-9 monoclonal antibody spe-
cific for a primate-conserved rhTRIM5α epitope and an
actin antibody as a cell lysate loading control. The results
(Figure 1A) showed that, in addition to the endogenous
human TRIM5α band at 56 kDa (present in the untrans-
duced JR5 cell lysate), there were bands at 59 and 57 kDa
in the hAgmTand hgorT lysates, respectively, correspond-
ing to the expected molecular masses (TRIM5α with the
HA-tag) of the hAgmTRIM5α and hgorTRIM5α proteins.
Similarly, the AgmT cell lysates contained bands at
56 kDa and 58 kDa, consistent with human and Agm-
TRIM5α proteins, respectively. In contrast, the gorT line
contained only one band at 56 kDa, yet with a greater
intensity relative to the bands in the other samples
(Figure 1A). Due to their nearly identical molecular mass,
ectopic gorilla and endogenous human TRIM5α proteins
co-migrate. Measurement of the fluorescence intensities
of both the xenogeneic and endogenous TRIM5α bands
and normalization by actin band signal revealed that the
range of ectopic TRIM5α expression was close to normal
physiological levels (Figure 1B), only 1- to 2-fold over that
of endogenous human TRIM5α among the different trans-
duced cell lines.
Xenogeneic TRIM5α expression modestly restricts HIV-1
and SIV single-round infection
The magnitude of TRIM5α restriction has been well
established by challenging cells with viral vectors or
defective GFP-expressing viruses [18,20-26]. To confirm
the viral inhibition effect of xenogeneic TRIM5α on
single-round infection in our cell lines, the AgmT and
gorT cells were exposed to either HIV-1 or SIV-based
lentiviral vectors that express GFP. Flow cytometry forGFP fluorescence revealed that AgmT cells exhibited
somewhat more resistance to HIV vector transduction
than the gorT cells, with a 4-fold compared to a 3-fold
resistance to infection, respectively (Figure 1C). These
results generally agree with prior published studies. To
examine infection in a more physiological system, the
xenogeneic TRIM5α-expressing cells were infected with
either HIV-1 or SIVmac239 and Gag-positive cells were
measured 40-h post-infection by intracellular flow cyto-
metry with CA antibodies. To control for non-specific
virion binding, the numbers of Gag-positive cells were
adjusted for the background present in the heat-
inactivated virus. The results were similar to those of the
vector-derived data: the infection of AgmT cells was 90%
lower for both viruses, and gorT cells demonstrated a
more modest reduction of infection, approximately 70%
(Figure 1D).
For comparison to the more extensively studied rhesus
macaque system, we examined the effect of xenogeneic
rhTRIM5α in our short-term infection assay. JR5 were
transduced with the Babe-rhT vector, which expresses
rhTRIM5α and puromycin acetyltransferase, and selec-
ted with puromycin to produce the rhT cell line. Immu-
noblot analysis of rhT lysates revealed only a single,
more intense TRIM5α-sized band due to the close mo-
lecular masses of rhTRIM5α and its human counterpart
(Figure 1A). Measurement of the bands found a 6-fold
increase in the TRIM5α over that of the JR5 controls
(Figure 1B), a higher level of exogenous expression that
the other JR5/TRIM5α cell lines. Consistent with prior
results, the rhTRIM5α-expressing cells reduced HIV-1
infectivity by an amount similar to that of the Agm-
TRIM5α proteins in the short term assay and did not
significantly affect SIV infection, as expected (Figure 1D).
Modest restriction was also observed by assaying HIV-1
and SIVmac239 in Agm- and gorTRIM5α-expressing
TZMbl cells (data not shown). Thus, in our systems,
xenogeneic expression of these three TRIM5α proteins
results in a modest level of restriction in single-round/
short-term assays and recapitulates most prior studies of
Agm- and rhTRIM5α [9,18,21-24,26-30].
Strong AgmTRIM5α replication restriction after a cell-free
challenge
To determine the effect of these TRIM5α proteins on ex-
tended replication, JR5, hAgmT, AgmT, hgorT, and gorT
cells were infected with cell-free stocks of HIV-1NL4-3 or
SIVmac239 from freshly prepared transfection supernatants
at 10-fold dilutions. Cells were cultured for 14 days with
periodic fluid changes before supernatants were harvested
and analyzed for the presence of virions by CA NIr immu-
noblot (Figure 2A). The HIV-1 cell-free challenge assays
showed that the JR5 cells had detectable p24CA bands out
to the 10-4 inoculum dilution, with no detectable signal in
Figure 1 Ecotopic expression in JR5 cells and infection assays.
(A). A NIr immunoblot of cell lysate samples is presented with
TRIM5α signal in red and actin in green. Samples are identified
above their respective lanes, with molecular mass standard sizes and
band identities displayed at the margins. (B). A graph of fluorescent
immunoblot signal intensities in the NIr blot relative to those of
the untransduced JR5 cells is presented with the amount of
endogenous, human TRIM5α-colored blue, xenogeneic TRIM5α
colored yellow, and co-migrating TRIM5α proteins colored green.
(C) A graph of flow cytometry analysis results for GFP signal from
single-round infectivity assays (MOI = 0.05) using HIV-1NL4-3 and
SIVmac239-expressing GFP vectors relative to the values for the JR5
positive controls is presented. (D) A graph of results of flow cytometry
analysis for intracellular CA 40-h post infection with either HIV-1NL4-3 or
SIVmac239 (MOI = 0.05) is presented. Graphs C and D are averages of
three independent experiments and error bars indicate standard
deviation. Statistical of the experimental versus the control values for
the data in both panels C and D generated p-values of <0.012 for all
pairs except for the rhTRIM5α/SIV sample, p = 0.37.
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to < 105. In contrast, supernatants from the hAgmT and
AgmT cultures had a slight p24CA signal in the neat in-
fection sample and no detectable signal in any of those
from virus dilution cultures (Figure 2A), indicating a
strong level of restriction induced by both versions of
TRIM5α, ≥ 103/<104 fold. In contrast, the hgorT and gorT
cultures had essentially the same levels of p24CA in the
challenge dilutions as the JR5 positive controls, with in-
tense p24CA bands in the neat through the 104 dilution
samples, indicating at least levels of replication similar to
those of JR5 (Figure 2A). This is expected given the
high level of conservation of between human and gorilla
TRIM5α genes [22].
A NIr immunoblot of virus samples from JR5 cultures
infected with the SIVmac239 dilution series revealed that
p28CA signals were detectable out to the 10-3 dilution
(Figure 2A), in part reflecting a lower susceptibility of
JR5 cells to infection by SIVmac239 than to HIV-1, a
phenomenon that we observe in most human cell lines
(D. Ott unpublished data). Similar to the HIV-1 results,
both hAgmT and AgmT cells showed a high level of re-
sistance with no p28CA signal detectable in any of the
supernatants from infected cells (Figure 2A), indicating a
resistance of ≥103. The cell-free SIV-challenged gorT
cells had little p28CA signal at the 10-3 dilution com-
pared to that of the JR5 control band while the hgorT
had little difference in intensity from the control at the
10-3 dilution (Figure 2A), indicating, at most, a 10-fold
level of restriction induced by gorTRIM5α, considerably
lower than that of AgmTRIM5α transduced cells.
Others have noted that overexpression of TRIM5α to
high levels (>50-fold) [20,51,52] or increasing the sta-
bility of TRIM5α [10] can result in restriction-like effects
in single-round experiments. While the amount of total
TRIM5α expression, both endogenous and exogneous,
Figure 2 Cell-free infection challenge assays. Representative CA
NIr immunoblots of HIV-1 and SIV virions in infected cell culture
supernatant samples from three independent experiments are
presented. Virus and infection dilutions are labeled above the blot.
Samples of the viral inocula (first lane), and supernatant samples
from untreated cells (second lane) and from 14-day cultures infected
at different dilutions (lanes 3–8) are presented above the blot panels. (A).
Results from HIVNL43 (left) and SIVmac 239 (right), and (B) from SIVAgmTan-1.
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2.5-fold in the transduced cell lines, it is possible that
these levels of over-expression might still cause nonspe-
cific restriction. To address this possibility, we examined
both JR5 and hAgmT cells in our replication assay with
SIVAgmTan-1, a cognate virus for AgmTRIM5α. The re-
sults showed no evidence of restriction in the hAgmT
cells, with nearly similar amounts p28CA signal detected
in the neat and 10-1 dilution samples and a slight signaldetected in the 10-2 dilution sample (Figure 2B). Thus,
the restriction patterns observed in these experiments
are not an artifact of TRIM5α overexpression and are
consistent with specific AgmTRIM5α-mediated restric-
tion of HIV-1 and SIVmac239. Taken together, these re-
sults indicate that AgmTRIM5α specifically restricts
HIV-1 and SIV, while gorTRIM5α fails to restrict HIV-1
and only weakly restricts SIV.
AgmTRIM5α restricts when challenged with infected cells
The cell-free virus challenge results presented above
demonstrate restriction in a culture in which all of the
cells express xenogeneic TRIM5α. However, cell-to-cell
infection, i.e., extracellular virions being transferred
across cell–cell contacts, is up to 1000-fold more effi-
cient than a cell-free challenge, [48,53-61]. To test re-
striction in our xenogeneic TRIM5α-expressing cells by
this more stringent challenge, AgmT and gorT cells were
cultured with either HIV-1 or SIV-infected JR5G cells,
JR5 cells that express GFP to differentiate the infected
challenge cells from the TRIM5α-transduced target cells
(Figures 3A and 4A), at increasing 10-fold ratios, ranging
from 50- to- 5 × 105 cells. After 12-days, the xenogeneic
TRIM5α-expressing cells in the mixed cultures were an-
alyzed for infection by intracellular Gag flow cytometry
using CA antibodies and gating on GFP negative cells
(Figure 3A).
The intracellular p24CA staining for Gag in the JR5 tar-
gets revealed the presence of 30% to 70% HIV-infected
JR5 cells in all of the mixed cultures (Figure 3B). Interest-
ingly, the cultures initiated with 500 JR5G-infected cells
contained the highest level of infected JR5 targets, 70%,
while the 5 × 105 cell culture contained only 30% (data not
shown), apparently due to cytopathology induced by the
presence of HIV-1 over the 12-day testing period. In con-
trast to the JR5 infection results, the AgmT target cells
had either background or considerably reduced levels of
Gag staining at the 50- and 500-infected-cell challenge
levels, 0.3% and 1% respectively (Figure 3B). The levels of
HIV-infected gorT in the various mixed culture ratios
mirrored the JR5 cultures, with only a minor reduction of
Gag-positive cells in the 50-cell culture (44%), compared
to the Gag-positive cells in the JR5 culture (55%). Thus,
gorTRIM5α-expressing cells demonstrated little, if any,
cell-to-cell restriction, similar to the cell-free challenge re-
sults. In contrast, cells expressing AgmTRIM5α exhibited
a 102 restrictive phenotype for HIV-1 replication.
Prior results reported by Richardson et al. expressing
rhTRIM5α in primary human CD4+ T cells observed
that restriction protected transduced cells from HIV-1,
but failed to do so when untransduced cells were also
present at the initial cell-free inoculation. Additional ex-
periments confirmed that this was due to cell-to-cell
transfer of HIV-1 from the infected xenogeneic TRIM5α
Figure 3 Flow cytometry analysis of HIVNL4-3 cell-to-cell challenge experiments. Representative analyses of 12-day mixed-cell cultures from
three independent experiments are presented. (A). Gating of mixed cell cultures (from top to bottom) for single cells, side scatter height by area
and forward scatter height by area plots, and for live cells, side scatter area by forward scatter area plots. An example of the gating of the input
infected JR5G cells from the JR5 and TRIM5α cultures is presented in the bottom plot (the 5 × 105 cells HIV-JR5G and 5 × 105 JR5 mixed culture
shown). (B). Flow cytometry analysis gating on the GFP– cells in the mixed cultures are presented with HIV CA staining on the X-axis and GFP
fluorescence in the Y-axis. Each series of 5 × 105 TRIM5α cultures are identified at left and the infected JR5G cells added are indicated over each
challenge group.
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[48]. To determine whether rhTRIM5α could restrict
HIV-1 in our assay, which is similar to the Richardson
assay, we tested rhT cells in our cell-to-cell challenge
assay. In contrast to the single-round assay, rhT cells
showed only marginal HIV-1 restriction at the 50-cell
challenge, 19% infected cells, compared to the JR5 con-
trol with 55% infected cells present, and essentially the
same frequency of infected cells in the 500-cell cultures
(Figure 3B). Thus, similar to the results reported by
Richardson et al., our results showed that rhTRIM5α
fails to restrict HIV-1 infection in this high multiplicity
of infection (MOI) cell-to-cell setting.
Flow cytometry of the SIV-mixed cultures found that, as
in our cell-free experiments, the extent of the SIVmac239
infection of the target JR5 cells, while robust, was less than
the extent of HIV-1 infection: SIV infection was clearly
evident at the 500-cell challenge, with 30% of the cells in-
fected (Figure 4B). The AgmT results were quite similarto those of the HIV-1 assay: the 500-cell challenge had
background staining and the 5 × 103-cell challenge culture
contained considerably reduced levels of infected cells, 1%
frequency, versus 38% for the JR5 control (Figure 4B).
Some restriction was even evident at the 5 × 104-cell chal-
lenge with 27% of the AgmT cells containing Gag com-
pared to 43% of the JR5 cells. As seen in the cell-free
infection experiments, the gorTcells displayed lower levels
of SIVmac239 restriction than AgmT cells, reducing the
number of infected cells in the 500-cell mixed culture to
5%, as compared to a 30% frequency for the JR5 control
and a 27% to 38% presence of infected cells in the 5 × 103-
cell challenge culture. As expected, rhT cells exhibited
only slightly fewer infected cells than the JR5 controls
(Figure 4). Taken together, these data show that Agm-
TRIM5α potently restricts both HIV-1 and SIVmac239,
even in this rigorous cell-to-cell challenge, while, as pre-
dicted by the cell-free assays, gorTRIM5α only modestly
restricts SIVMAC239.
Figure 4 Flow cytometry analysis of SIVmac239 cell-to-cell challenge experiments. Representative analyses of 12-day mixed-cell cultures from
three independent experiments are presented. (A). Gating of mixed cell cultures (from top to bottom) for single cells, side scatter height by area
and forward scatter height by area plots, and for live cells, side scatter area by forward scatter area plots. An example of the gating of the input
infected JR5G cells from the JR5 and TRIM5α cultures is presented in the bottom plot (the 5 × 105 cells SIV-JR5G and 5 × 105 JR5 mixed culture
shown). (B). Flow cytometry analysis gating on the GFP– cells in the mixed cultures are presented with SIV CA staining on the X-axis and GFP
fluorescence in the Y-axis. Each series of 5 × 105 TRIM5α cultures are identified at left and the infected JR5G cells added are indicated over each
challenge group.
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lower virus production
The strength of AgmTRIM5α restriction of HIV-1 and
SIV in both the cell-free and, especially, the cell-to-cell
replication assays is unexpected since its influence on
single-round infection was fairly modest. One formal
possibility for the discrepancy between the replication
and single-round infection results is that the expression
of xenogeneic TRIM5α in our cells decreases virus
production. Previous reports indicated that xenogeneic
expression of TRIM5α can reduce the amount of infec-
tious virions produced from cells [51,62], though these
observations remain controversial [20,52,63]. To for-
mally rule out lower virion production from infected
cells by our xenogeneic TRIM5α expression approach as
a possible mechanism for our results, we investigated
whether the expression of AgmTRIM5α or gorTRIM5α
reduces virus release from infected cells. We transduced
two human CD4+ T-cell lines, Clone 4 [64] (cloned from
HIV-infected H9 cells) and E11S [65] (cloned from SIV-infected HuT 78 cells), which produce high constitutive
levels of HIV-1 or SIV, respectively with the SMS-
hAgmT or SMS-hgorT vectors. Transductants were se-
lected for puromycin resistance and confirmed by GFP
fluorescence, producing the Clone 4 lines Cl4/hAgmT
and Cl4/hgorT and the E11S lines, E11S/hAgmT and
E11S/hgorT. Quantitative NIr-immunoblot analysis of
Clone 4 and E11S transductant cell lysates revealed that
exogenous TRIM5α was expressed at least 2- to 5-fold
more than the endogenous human protein (Figure 5B),
higher than the 1- to 2-fold level observed in the JR5
transductants (Figure 1B).
The production of virions from Clone 4 and E11S and
their xenogeneic TRIM5α transductants was measured
by isolating virions and cells after a 6-h incubation and
analyzing sample lysates by quantitative NIr immuno-
blotting with CA antibodies. From these data, the release
rate was calculated as the amount of CA fluorescent
signal in the supernatant divided by the total signal de-
tected, i.e. that amount present in both the virions and
Figure 5 Ectopic expression of TRIM5α in Clone 4 and E11S cells,
virion production, and infection assays. (A). NIr immunoblot of cell
lysate samples, with TRIM5α signal in red and actin in green are
presented. Samples are identified above their respective lanes.
Molecular mass standard sizes are displayed at left and band identities
at right. (B). Graph of fluorescent immunoblot signal intensities in the
NIr blot relative to those in the untransduced Clone 4 or E11S cells are
presented with the amount of endogenous, human TRIM5α-colored
blue, xenogeneic TRIM5α colored yellow, and co-migrating TRIM5α
proteins colored green. (C). Graph of relative virus release (virus in
supernatant/virus in cells and supernatant at 6 h) is presented. (D). A
graph of relative virus-specific infectivity (virus infectivity after a 6-h
collection period normalized by CA signal). Graphs shown in (C) and
(D) represent averages of three independent experiments, and error
bars indicate standard deviation.
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tion of virions from untransduced and transduced cell
lines (Figure 5B). Comparing calculations from three
independent experiments showed no significant differ-
ences in release between the untransduced and TRIM5α-
expressing cell lines. Taken together, these data indicate
that virion production is not reduced by xenogeneic
TRIM5α transduction and thus is not a factor in the in-
creased potency of AgmTRIM5α restriction of replication.
Xenogeneic TRIM5α expression has no effect on
infectious virion production
Even though release is normal, it is possible that the
virus produced from our xenogeneic TRIM5α transduc-
tants is less infectious than the virus produced from the
untransduced cells because of a subtle defect in assembly
or maturation. To examine this possibility, the specific in-
fectivity of the virions produced by the Clone 4 and E11S
cell lines was measured by the Tat-complementation
TZMbl beta-galactosidase focus-forming assay and nor-
malized by the amount of CA in the medium as measured
by NIr immunoblot quantitation to calculate specific
infectivity of each sample. The results showed that the
expression of xenogeneic TRIM5α had no measurable
effect on the specific infectivity of the virions produced
from cells (Figure 5C). This finding, together with the
release data, formally rule out late replication defects as
the reason for the potency of AgmTRIM5α replication
restriction.
Discussion
Our results identify TRIM5α from tantalus African
green monkey as an effective restriction factor of HIV-1
and SIV replication in CD4+ T cells, producing very po-
tent restriction of both HIV-1 and SIV replication, ap-
proximately ≥10-3 in the cell-free challenge and ≥10-2 in
the more rigorous infected cell challenge system. The
ability of AgmTRIM5α to restrict in the context of a
cell-to-cell challenge is remarkable considering that this
Coren et al. Retrovirology  (2015) 12:11 Page 9 of 14mode of infection is up to 1000-fold more efficient than
the cell-free infection challenge [48,55-61]. In compari-
son, rhTRIM5α fails to restrict HIV-1 replication in our
cell-to-cell challenge assay, even though it exhibits es-
sentially equivalent levels of restriction in our short term
infection assay as AgmTRIM5α. Furthermore, as dis-
cussed above, primary human CD4+ T cells transduced
with rhTRIM5α or stabilized human TRIM5α genes re-
strict HIV-1 replication, yet fail to do so in cell-to-cell
contact with untransduced infected cells [10,48], condi-
tions similar to our cell-to-cell challenge. Similarly,
Ohkura et al. found that N-tropic murine leukemia virus
produced restriction resistant mutants in target cells
expressing either human or rhesus TRIM5α only when
co-cultured with unmodifed cells, indicating a low
level of infection in the mixed cultures that was ab-
sent with the modified cells alone [66,67]. Therefore,
AgmTRIM5α is unique among TRIM5α proteins studied
to date in that it can restrict both HIV-1 and SIV in the
severe test afforded by the cell-to-cell challenge in the
presence infected non-expressing cells.
It is important to note that after the initial challenge,
our cell-free experiments develop a cell-to-cell infection
component. After the inoculum is absorbed, the first gen-
eration of productively infected cells can initiate the next
round of replication by both cell-free and cell-to-cell in-
fection. Because all of the cells express AgmTRIM5α in
the cell-free assay, the initial levels of infected cells are
low, thus limiting the opportunity for cell-to-cell transmis-
sion. It is important to consider that TRIM5α-mediated
restriction is saturable, resistance being overcome by the
presence of enough capsid cores to bind and sequester
the xenogeneic TRIM5α and neutralize restriction. When
every target cell in a culture expresses AgmTRIM5α
enough virus needs to enter the cells to saturate the xeno-
geneic TRIM5α. Since the amount of virions produced
from the initial infection is low in the presence of Agm-
TRIM5α, the resulting MOI, either cell-free or cell-to-cell,
generated by the cells infected in the second round is in-
sufficient to saturate TRIM5α in many cells and fails to
support spread of infected cells in the subsequent rounds
of replication. In contrast, our cell-to-cell experiments ini-
tially have infected JR5G cells, thus provide a stronger
challenge to restriction which more readily overwhelms
the resistance in AgmTRIM5α-expressing targets, resul-
ting in a lower, yet still considerable, level of restriction.
The nature of TRIM5α restriction also can explain the
counter-intuitive relationship between the single-round
infection and replication assays. In most cases of retro-
viral inhibition by other resistance factors or anti-viral
compounds, the decrease in infectivity follows linear
kinetics: the level of inhibition is directly proportional to
that of the agent/defect. In contrast, the suppression of
TRIM5α restriction exhibits multi-hit kinetics: manyintact capsid cores need to enter the cell to saturate
the cooperatively binding TRIM5α, before the strong
anti-viral block to infection is removed. Thus, capsid
core–mediated saturation of TRIM5α restriction follows
logarithmic kinetics with a strong, nearly absolute, block
at lower MOIs that initially has small marginal reduc-
tions in restriction with increasing virus exposure. Be-
cause restriction requires cooperative TRIM5α binding
to intact capsid cores [41,42,68], as the amount of
restricting TRIM5α in the cell is reduced by binding to
the cores, incremental dosages of capsid cores have lar-
ger marginal effects on saturating TRIM5α restriction
[41,68-71]. After TRIM5α is saturated, infection occurs
without restriction. Therefore, subsequent rounds of in-
fection initially face a near-absolute block mediated by
TRIM5α restriction which requires enough capsid cores
to overcome this restriction hurdle and productively in-
fect cells. In this way, a modest block has a cumulative
effect, being amplified by the amount of virus needed to
surmount the restriction hurdle at each round of replica-
tion. Indeed, Ohkura et al. observed nearly absolute re-
striction to replication in an N-tropic murine leukemia
virus/rhTRIM5α system that was negligible at a 10-fold
higher MOI, consistent with this restriction hurdle model
[66]. In addition to the inherent nature of TRIM5α restric-
tion, other cellular and viral factors can come into play.
For instance, a spreading infection can also be limited by
virus-induced cell death and the spontaneous decay of vi-
rions in the cell culture supernatant [72,73], both of which
remove sources of infection.
Given this cumulative restriction hurdle model, the
failure of gorTRIM5α to effectively restrict SIV replication
in either assay can be explained by the lower efficacy of
gorTRIM5α restriction observed in the single-round and
short term infection assays. For gorTRIM5α, the restric-
tive barrier to infection, although reducing SIV single-
round infection by 70%, does not appear to present a high
enough of a restriction hurdle to have a cumulative effect
for replication.
Taken together, AgmTRIM5α appears to be superior
to other TRIM5α in restricting both HIV-1 and SIV
when expressed at near-physiological levels. Despite ob-
serving inhibition of infection that was comparable to
that of AgmTRIM5α in a single-round infection assay,
rhTRIM5α failed to restrict in our cell-to-cell assay.
While these two proteins are fairly homologous, Agm-
TRIM5α contains a 37–amino acid region with a unique
20-amino acid duplication in the B30.2(SPRY) domain
which forms the basis of SIVmac restriction [22,30] and
is likely to be a factor for its superior potency against
HIV-1 replication. Additionally, the basic restriction
mechanism for AgmTRIM5α restriction appears to have
different requirements than those of rhTRIM5α, notably
E3 ubiquitin ligase activity [32]. With its B30.2(SPRY)
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TRIM5α proteins [24], and this feature may be the rea-
son for the exceptional restriction of cell-to-cell infec-
tion. Fine mapping of the critical residues in this region
of B30.2(SPRY) responsible for the elite restriction by
AgmTRIM5α and their interactions with HIV-1 capsid
should yield important information about the mecha-
nism for effective TRIM5α restriction.
The restrictive properties of TRIM5α have been pro-
posed as the basis of anti-viral therapies [1,2,8,10,49].
Our results showing effective AgmTRIM5α-mediated
restriction of HIV-1 and SIVmac239 in CD4
+ T cells are
consistent with the use of the TRIM5α restriction
mechanism as an anti-HIV/SIV approach. Indeed, Shi
et al. have described a small-molecule inhibitor that
prematurely uncoats the HIV-1 capsid core after viral
entry [74]. While TRIM5α restriction is clearly satur-
able and thus not an absolute block to infection, it
can and does slow the spread of virus in target cells. In-
deed, experiments in primary rhesus CD4+ T cells show
that AgmTRIM5α offers significant protection from
SIVmac239 thereby enhancing their antiviral function (SJ,
MTT, VIA, CO, and DEO manuscript submitted). Our
results open up the SIV/rhesus macaque model for
in vivo studies of TRIM5α restriction. Of course, one
consideration for using any xenogeneic TRIM5α as a
protective therapy is whether it will induce an adverse
immune response in the recipient [8]. While this is
likely to preclude the direct use of AgmTRIM5α as a
therapeutic, the nature of TRIM5α is a facet of AIDS
virus biology that is important to understand and po-
tentially harness.
Conclusions
Using a dilution end-point replication assay, we find
that AgmTRIM5α exhibits a greater than 103-fold level
of restriction of HIV-1 and SIVmac239 replication in a
transformed human CD4+ T-cell line when expressed
at near physiological levels. This level of restriction was
markedly greater than the restriction observed in
single-round or short term infectivity assays, indicating
restriction building up cumulatively over many rounds
of replication. Additionally, AgmTRIM5α could restrict
HIV-1 and SIVmac239 replication in co-culture with
infected normal cells. In contrast, rhTRIM5α failed to
effectively restrict HIV-1 in co-culture, a finding pre-
viously observed for both rhTRIM5α and a stabilized
mutant human TRIM5α exhibiting an extended half-
life. Thus, AgmTRIM5α is unique among the TRIM5α
proteins tested to date. These results provide a basis for
directly examining TRIM5α restriction in the SIV/
rhesus macaque model to better understand and po-
tentially utilize this anti-AIDS virus mechanism in
the clinic.Methods
Viruses and cells
293T human embryonic kidney, Phoenix RD114 (clone
22) [75] and TZM-bl [76] (also known as JC53-BL clone
13) cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM L-glutamine, 100 U
per ml penicillin, 100 μg per ml streptomycin and 10%
vol/vol fetal bovine serum. Jurkat CCR5, Clone 4, and
E11S cell lines were cultured in RPMI 1640 with the
same supplements as those in the 293 T cell medium. All
cell culture products were obtained from Life Technologies,
Inc. All transient transfections of 293T cells were carried
out using TransIt293 (Mirus Bio Corp.). HIV-1, SIVmac239,
and SIVAgm stocks were produced by transfecting
HEK293T cells with pNL4-3 [77], p239macSPXL (gift of
Ronald Desrosiers) [78-80], or pSIVAgmTan-1 [81] (obtained
through the National Institutes of Health [NIH] AIDS
Reagent Program, Division of AIDS, National Institute
of Allergy and Infectious Diseases [NIAID], NIH, from
Drs. Marcelo Soares and Beatrice Hahn). Viral and viral
vector supernatants were passed through a 0.45 μ filter be-
fore use. Short term infections were carried out in the
presence of 2 μg/mg hexadimethrine bromide at an MOI
of 0.05.
Retroviral vectors and generation of cell lines
Agm- and gorTRIM5α genes [22] were a kind gift of
Theodora Hatziioannou (Aaron Diamond AIDS Research
Center, New York, NY). The rhesus (rh) gene (Cat#
10072) was obtained from the NIH AIDS Repository Pro-
gram, Pathogenesis and Basic Research Branch, Division
of AIDS, NIAID, Bethesda, MD). Agm-, gor-, and
rhTRIM5α genes were cloned into a modified MSCV PIG
retroviral vector (obtained from Addgene , plasmid 18751,
deposited by Scott Lowe) with an N-terminal hemag-
glutinin epitope tag (YPYDVPDYA) added to the TRIM5α
coding sequence to produce pSMS-Agm, pSMS-gor, and
pSMS-rh vector constructs that also express both the
puromycin resistance and GFP genes. The three TRIM5α
genes were also cloned into the pBabe-puro retroviral
vector [82], obtained from Addgene, plasmid 1764,
contributed by Bob Weinberg to produce pBabe-Agm,
pBabe-gor, and pBabe-rh vector constructs. Retroviral vec-
tors were packaged by transient transfection of Phoenix
RD114 packaging cells [75] (kind gift of Hans-Peter Kleim,
Fred Hutchinson Cancer Research Center, Seattle, WA).
GFP-expressing JR5 cells were produced by transduction
with a GAE-SFFV-GFP-WPRE lentiviral vector DNA
(kind gift of Francois-Loic Cosset, Inserm Lyon, France)
[83] that was modified by fusion of a P2A-puroTK cas-
sette to the C-terminus of GPF to produce the GSPK
vector that expresses GFP, and a puromycin-herpes thymi-
dine kinase fusion gene. The GSPK lentiviral vector was
produced by transiently cotransfecting HEK293T cells
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plasmid [83] (kind gift of F-L Cosset) and pLPVSVG, at a
ratio of 4.5:4.1:1 by mass. GFP-expressing LKO HIV lenti-
viral vector (GE Healthcare Dharmacon, Piscataway, NJ)
was packaged using the Virapower packaging system (Life
Technologies) in transfected 293 T cells. Supernatants
were collected 48 h post-transfection and passed through
a 0.45 μ filter. Transductions were carried out in the pre-
sence of 2 μg/mg hexadimethrine bromide and Viromag
R/L reagent (Boca Scientific, Inc.), the latter reagent con-
centrating supernatants to deliver a higher MOI. TRIM5α
vector transductants were selected for puromycin re-
sistance. Puromycin (Sigma-Adlrich Inc.) selection was
carried out at 2 μg/ml. For single-round infectivity assays,
transductions were carried out at an MOI of 0.05.
Virus and cell lysate preparation and isolation
HIV-1-containing cell culture supernatants were clarified
by centrifugation at 2,000 × g for 5 min at 4°C, and then
samples directly lysed in a one-half volume of SDS-
PAGE loading buffer (250 mM Tris-Cl pH 6.8, 8% so-
dium dodecyl sulfate, 4% vol/vol β-mercaptoethanol,
40% vol/vol glycerol, and 0.02% bromophenol brilliant
blue). SIV-containing cell culture supernatants were cla-
rified and then concentrated 10-fold using the Lenti-X
virion concentration reagent (Clontech Laboratories)
according to the manufacturer’s instructions. Precipitated
virions were lysed directly in SDS-PAGE gel loading buf-
fer. Cell samples were collected and washed once with
ice-cold Dulbecco’s phosphate-buffered saline solution
without Ca+2 or Mg+2 (D-PBS, Life Technologies) and
then lysed with prechilled 10 mM Tris HCl pH 7.5, 0.1%
SDS, 5 μg of phenylmethanesulfonyl floride and 4 U/μl of
Omnicleave® nuclease (Epicentre Biotechnologies), incu-
bated for 2 h at 4°C and treated with an equal volume of
SDS-PAGE gel loading buffer.
Near infrared (NIr) immunoblots
Samples were separated by SDS-PAGE electrophoresis
and blotted onto PVDF-FL membranes (Millipore) using
a semi-dry apparatus as previously described [84]. Blots
were blocked for at least 1 h in Odyssey blocking buffer
(LI-COR Biosciences) and then incubated in blocking
buffer with one or two primary antiserum (a)/antibody
(ies) for at least 2 h, typically overnight. Blots were
washed twice with blocking buffer for 10 m then in-
cubated with the appropriate donkey IRDye 800CW
and/or IRDye680 LT fluorescently labeled secondary
antibodies (LI-COR) at a 1:10,000 ratio vol/vol in block-
ing buffer for at least 2 h. Blots were washed five times
for 10 min each time in blocking buffer, and then analyzed
with an Odyssey infrared imaging system (LI-COR) using
a laser intensity of between 1 and 5. Signal densities of
bands were measured by the Odyssey 3.0 applicationsoftware. All blotting steps were carried out at room
temperature. Monoclonal antibodies used were anti-
rhTRIM5α, clone 3F1-1-9, (Cat# 12271, NIH AIDS
Reagent Program) and anti-beta actin (Cat# 60008-1-Ig,
ProteinTech Group). Primary goat antiserum against HIV
p24CA/SIV p27CA (goat #81) was obtained from the AIDS
and Cancer Virus Program, Frederick National Laboratory
for Cancer Research , Frederick, MD.
Virus release assays
Virus release was carried out as previously described
[85]. Briefly, 5 × 106 cells were collected by centrifuga-
tion, washed twice with PBS and then placed in 5 ml of
pre-warmed medium and incubated at 37°C. At 6 h,
virus and cell lysates were prepared and analyzed by
quantitative CA near infrared NIr immunoblot. Release
factors for the viruses were determined by dividing the
measured CA fluorescence values for the virus samples
(arbitrary units) by the total Gag signal (virus + cellular
Gag) to produce a release factor. The cellular Gag values
were corrected for loading and cell extract processing
differences by normalizing signals from actin staining
with a second color.
Specific infectivity assays
Specific infectivity assays were carried out over a 6-h
time period using the same procedure as the virus re-
lease assay presented above with clarified supernatants
assayed for infectivity and virion lysate samples were
prepared. Infectivity assays were performed using the
TZM-bl single-round lacZ Tat complementation assay
as previously described [86]. CA present in the super-
natant was measured by CA NIr immunoblot. Specific
infectivity was calculated dividing the virus titer by the
CA band signal, expressed in blue cell-forming units per
arbitrary CA fluorescence value. Heat inactivation was
carried out at 70°C for 20 min.
Flow cytometry analysis of infected cell lines
For each sample, medium containing 1-2 × 106 cells was
centrifuged at 400 × g for 5 min and fixed in 0.5 ml of 4%
wt/vol paraformaldehyde in D-PBS (Life Technologies) for
20 min at room temperature followed by the addition of
3.5 ml permeabilization solution (PS), 0.1% (wt/vol) sap-
onin (Sigma-Aldrich) in D-PBS, and incubation at room
temperature for 10 min. Cells were then collected by cen-
trifugation at 550 × g for 5 min, followed by 2 washes with
PS. Cells were then stained with KC57 antibody for HIV-1
CA (Beckman-Coulter, Inc.) or 2 F12 antibody for SIV CA
(Quality Biological, Inc., Gaithersburg, MD) in 100 μl of
PS for 30 min in the dark at 4°C, washed twice in 4 ml of
PS and then resuspended in 200 μl of PS, and analyzed
immediately by an LSRII flow cytometer (BD Biosciences)
Coren et al. Retrovirology  (2015) 12:11 Page 12 of 14Data analysis was performed using FCS Express software
(De Novo Software).
Statistical analysis
Single-round and short term infectivity data where
analyzed using the Student’s t-Test function in Excel
(Microsoft Inc.) with paired two-tailed parameters.
Ethical approval
All research was carried out under approval by the NCI
at Frederick Institutional Biosafety Committee # 11-03
superseded by #14-23.
Competing interests
The authors declare that they have on competing interests.
Authors’ contributions
LVC produced the vector constructs and the immunoblots, MTT and VIA
carried out flow cytometry analyses, SJ performed infectivity assays and
some cell culture, GQDP contributed experimental design, CO contributed
experimental design, data interpretation and manuscript assistance, DEO
conceived and designed the study, produced cell lines, carried out infectivity
and replication, complied data and wrote the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
We thank Theodora Hatziioannou for the African green monkey and gorilla
TRIM5α genes, Hans-Peter Kleim for the Phoenix RD114 clone 22 packaging
cell line, Francois-Loic Cosset for the GAE-SFFV-GFP-WPRE lentiviral vector
DNA, and Rob Gorelick for helpful advice. The following reagents were
obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID,
NIH: Cat# 12271 Anti-rhTRIM5α (3 F1-1-9), deposited by Tom Hope and Wes
Sundquist; Cat# 3444 pSIVAgmTan-1 plasmid, deposited by Marcelo Soares and
Beatrice Hahn; rhTRIM5α gene, deposited by Joseph Sodroski and Matt
Stremlau; Cat# 10072; 2 F12 SIV p27 hybridoma, Cat#1547, deposited by Niels
Pedersen. This project has been funded in whole or in part with federal
funds from the National Cancer Institute, National Institutes of Health, under
contract no. HHSN261200800001E. The content of this publication does not
necessarily reflect the views or policies of the Department of Health and
Human Services, nor does mention of trade names, commercial products, or
organizations imply endorsement by the U.S. Government.
Received: 16 October 2014 Accepted: 8 January 2015
References
1. Greene WC, Debyser Z, Ikeda Y, Freed EO, Stephens E, Yonemoto W, et al.
Novel targets for HIV therapy. Antiviral Res. 2008;80:251–65.
2. Anderson J, Akkina R. Human immunodeficiency virus type 1 restriction by
human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+)
cell-derived macrophages in vitro and in T cells in vivo in severe combined
immunodeficient (SCID-hu) mice transplanted with human fetal tissue.
Hum Gene Ther. 2008;19:217–28.
3. Anderson JS. Using TRIM5alpha as an HIV therapeutic: the alpha gene?
Expert Opin Biol Ther. 2013;13:1029–38.
4. Chan E, Towers GJ, Qasim W. Gene therapy strategies to exploit TRIM
derived restriction factors against HIV-1. Viruses. 2014;6:243–63.
5. Sloan RD, Wainberg MA. Harnessing the therapeutic potential of host
antiviral restriction factors that target HIV. Expert Rev Anti Infect Ther.
2013;11:1–4.
6. Zhang J, Ge W, Zhan P, De Clercq E, Liu X. Retroviral restriction factors
TRIM5alpha: therapeutic strategy to inhibit HIV-1 replication. Curr Med
Chem. 2011;18:2649–54.
7. Nakayama EE, Shioda T. Anti-retroviral activity of TRIM5 alpha. Rev Med Virol.
2010;20:77–92.
8. Neagu MR, Ziegler P, Pertel T, Strambio-De-Castillia C, Grutter C, Martinetti
G, et al. Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins
engineered from human components. J Clin Invest. 2009;119:3035–47.9. Stremlau M, Perron M, Welikala S, Sodroski J. Species-specific variation in
the B30.2(SPRY) domain of TRIM5alpha determines the potency of human
immunodeficiency virus restriction. J Virol. 2005;79:3139–45.
10. Richardson MW, Guo L, Xin F, Yang X, Riley JL. Stabilized human TRIM5alpha
protects human T cells from HIV-1 infection. Mol Ther. 2014;22:1084–95.
11. Malim MH, Bieniasz PD. HIV Restriction Factors and Mechanisms of Evasion.
Cold Spring Harb Perspect Med. 2012;2:a006940.
12. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, et al. The tripartite
motif family identifies cell compartments. EMBO J. 2001;20:2140–51.
13. Li X, Gold B, O’HUigin C, Diaz-Griffero F, Song B, Si Z, et al. Unique features
of TRIM5alpha among closely related human TRIM family members.
Virology. 2007;360:419–33.
14. Sastri J, Campbell EM. Recent insights into the mechanism and
consequences of TRIM5alpha retroviral restriction. AIDS Res Hum
Retroviruses. 2011;27:231–8.
15. Gartner S, Liu Y, Polonis V, Lewis MG, Elkins WR, Hunter EA, et al. Adaptation
of HIV-1 to pigtailed macaques. J Med Primatol. 1994;23:155–63.
16. Himathongkham S, Luciw PA. Restriction of HIV-1 (subtype B) replication at
the entry step in rhesus macaque cells. Virology. 1996;219:485–8.
17. Shibata R, Kawamura M, Sakai H, Hayami M, Ishimoto A, Adachi A.
Generation of a chimeric human and simian immunodeficiency virus
infectious to monkey peripheral blood mononuclear cells. J Virol.
1991;65:3514–20.
18. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The
cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old
World monkeys. Nature. 2004;427:848–53.
19. Owens CM, Song B, Perron MJ, Yang PC, Stremlau M, Sodroski J. Binding
and susceptibility to postentry restriction factors in monkey cells are
specified by distinct regions of the human immunodeficiency virus type 1
capsid. J Virol. 2004;78:5423–37.
20. Zhang F, Perez-Caballero D, Hatziioannou T, Bieniasz PD. No effect of
endogenous TRIM5alpha on HIV-1 production. Nat Med. 2008;14:235–6.
author reply 236-238.
21. Hatziioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus
resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
Proc Natl Acad Sci U S A. 2004;101:10774–9.
22. Kratovac Z, Virgen CA, Bibollet-Ruche F, Hahn BH, Bieniasz PD, Hatziioannou
T. Primate lentivirus capsid sensitivity to TRIM5 proteins. J Virol.
2008;82:6772–7.
23. Keckesova Z, Ylinen LM, Towers GJ. The human and African green monkey
TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
Proc Natl Acad Sci U S A. 2004;101:10780–5.
24. Song B, Javanbakht H, Perron M, Park DH, Stremlau M, Sodroski J. Retrovirus
restriction by TRIM5alpha variants from Old World and New World primates.
J Virol. 2005;79:3930–7.
25. Goldschmidt V, Ciuffi A, Ortiz M, Brawand D, Munoz M, Kaessmann H, et al.
Antiretroviral activity of ancestral TRIM5alpha. J Virol. 2008;82:2089–96.
26. Yap MW, Nisole S, Lynch C, Stoye JP. Trim5alpha protein restricts both HIV-1
and murine leukemia virus. Proc Natl Acad Sci U S A. 2004;101:10786–91.
27. Yap MW, Nisole S, Stoye JP. A single amino acid change in the SPRY
domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol.
2005;15:73–8.
28. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate
TRIM5alpha identifies a critical species-specific retroviral restriction domain.
Proc Natl Acad Sci U S A. 2005;102:2832–7.
29. Perez-Caballero D, Hatziioannou T, Yang A, Cowan S, Bieniasz PD. Human
tripartite motif 5alpha domains responsible for retrovirus restriction activity
and specificity. J Virol. 2005;79:8969–78.
30. Nakayama EE, Miyoshi H, Nagai Y, Shioda T. A specific region of 37 amino
acid residues in the SPRY (B30.2) domain of African green monkey
TRIM5alpha determines species-specific restriction of simian immunodeficiency
virus SIVmac infection. J Virol. 2005;79:8870–7.
31. Maegawa H, Miyamoto T, Sakuragi J, Shioda T, Nakayama EE. Contribution
of RING domain to retrovirus restriction by TRIM5alpha depends on
combination of host and virus. Virology. 2010;399:212–20.
32. Kim J, Tipper C, Sodroski J. Role of TRIM5alpha RING domain E3 ubiquitin
ligase activity in capsid disassembly, reverse transcription blockade, and
restriction of simian immunodeficiency virus. J Virol. 2011;85:8116–32.
33. Javanbakht H, Diaz-Griffero F, Stremlau M, Si Z, Sodroski J. The contribution
of RING and B-box 2 domains to retroviral restriction mediated by monkey
TRIM5alpha. J Biol Chem. 2005;280:26933–40.
Coren et al. Retrovirology  (2015) 12:11 Page 13 of 1434. Diaz-Griffero F, Kar A, Lee M, Stremlau M, Poeschla E, Sodroski J.
Comparative requirements for the restriction of retrovirus infection by
TRIM5alpha and TRIMCyp. Virology. 2007;369:400–10.
35. Kutluay SB, Perez-Caballero D, Bieniasz PD. Fates of retroviral core
components during unrestricted and TRIM5-restricted infection. PLoS Pathog.
2013;9:e1003214.
36. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. Proteasome
inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse
transcription and infection. Proc Natl Acad Sci U S A. 2006;103:7465–70.
37. Perez-Caballero D, Hatziioannou T, Zhang F, Cowan S, Bieniasz PD.
Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs
with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and
proteasome activity. J Virol. 2005;79:15567–72.
38. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation.
Cold Spring Harb Perspect Med. 2012;2:a006924.
39. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. Functional surfaces of
the human immunodeficiency virus type 1 capsid protein. J Virol.
2003;77:5439–50.
40. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. Formation of a
human immunodeficiency virus type 1 core of optimal stability is crucial for
viral replication. J Virol. 2002;76:5667–77.
41. Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist
WI, Yeager M. Hexagonal assembly of a restricting TRIM5alpha protein.
Proc Natl Acad Sci U S A. 2011;108:534–9.
42. Shi J, Friedman DB, Aiken C. Retrovirus restriction by TRIM5 proteins
requires recognition of only a small fraction of viral capsid subunits. J Virol.
2013;87:9271–8.
43. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, et al. Specific
recognition and accelerated uncoating of retroviral capsids by the
TRIM5alpha restriction factor. Proc Natl Acad Sci U S A. 2006;103:5514–9.
44. Perron MJ, Stremlau M, Lee M, Javanbakht H, Song B, Sodroski J. The
human TRIM5alpha restriction factor mediates accelerated uncoating of the
N-tropic murine leukemia virus capsid. J Virol. 2007;81:2138–48.
45. Roa A, Hayashi F, Yang Y, Lienlaf M, Zhou J, Shi J, et al. RING domain
mutations uncouple TRIM5alpha restriction of HIV-1 from inhibition of
reverse transcription and acceleration of uncoating. J Virol. 2012;86:1717–27.
46. Danielson CM, Cianci GC, Hope TJ. Recruitment and dynamics of
proteasome association with rhTRIM5alpha cytoplasmic complexes during
HIV-1 infection. Traffic. 2012;13:1206–17.
47. Pertel T, Hausmann S, Morger D, Zuger S, Guerra J, Lascano J, et al. TRIM5 is
an innate immune sensor for the retrovirus capsid lattice. Nature.
2011;472:361–5.
48. Richardson MW, Carroll RG, Stremlau M, Korokhov N, Humeau LM,
Silvestri G, et al. Mode of transmission affects the sensitivity of human
immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. J Virol.
2008;82:11117–28.
49. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Inhibition of HIV-1 replication by
simian restriction factors, TRIM5alpha and APOBEC3G. Gene Ther.
2007;14:185–9.
50. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev
Microbiol. 2012;10:852–67.
51. Ohmine S, Sakuma R, Sakuma T, Thatava T, Takeuchi H, Ikeda Y. The antiviral
spectra of TRIM5alpha orthologues and human TRIM family proteins against
lentiviral production. PLoS One. 2011;6:e16121.
52. Uchil PD, Quinlan BD, Chan WT, Luna JM, Mothes W. TRIM E3 ligases
interfere with early and late stages of the retroviral life cycle. PLoS Pathog.
2008;4:e16.
53. Gousset K, Ablan SD, Coren LV, Ono A, Soheilian F, Nagashima K, et al.
Real-time visualization of HIV-1 Gag trafficking in infected macrophages.
PLoS Pathog. 2008;4:e1000015.
54. Pearce-Pratt R, Malamud D, Phillips DM. Role of the cytoskeleton in
cell-to-cell transmission of human immunodeficiency virus. J Virol.
1994;68:2898–905.
55. Sattentau QJ. The direct passage of animal viruses between cells. Curr Opin
Virol. 2011;1:396–402.
56. Dimitrov DS, Willey RL, Sato H, Chang L-J, Blumenthal R, Martin MA.
Quantitation of human immunodeficiency virus type 1 infection kinetics.
J Virol. 1993;67:2182–90.
57. Carr JM, Hocking H, Li P, Burrell CJ. Rapid and efficient cell-to-cell transmission
of human immunodeficiency virus infection from monocyte-derived
macrophages to peripheral blood lymphocytes. Virology. 1999;265:319–29.58. Chen P, Hubner W, Spinelli MA, Chen BK. Predominant mode of human
immunodeficiency virus transfer between T cells is mediated by sustained
Env-dependent neutralization-resistant virological synapses. J Virol.
2007;81:12582–95.
59. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient
human immunodeficiency virus replication in mobile lymphocytes. J Virol.
2007;81:1000–12.
60. Zhong P, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, et al.
Cell-to-cell transmission can overcome multiple donor and target cell
barriers imposed on cell-free HIV. PLoS One. 2013;8:e53138.
61. Martin N, Welsch S, Jolly C, Briggs JA, Vaux D, Sattentau QJ. Virological
synapse-mediated spread of human immunodeficiency virus type 1
between T cells is sensitive to entry inhibition. J Virol. 2010;84:3516–27.
62. Sakuma R, Noser JA, Ohmine S, Ikeda Y. Rhesus monkey TRIM5alpha restricts
HIV-1 production through rapid degradation of viral Gag polyproteins.
Nat Med. 2007;13:631–5.
63. Sakuma R, Ohmine S, Mael AA, Noser JA, Ikeda Y. Author reply to comment
on Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid
degradation of viral Gag polyproteins. Nat Med. 2008;14:235–6.
64. Ott DE, Nigida Jr SM, Henderson LE, Arthur LO. The majority of cells are
superinfected in a cloned cell line that produces high levels of human
immunodeficiency virus type 1 strain MN. J Virol. 1995;69:2443–50.
65. Benveniste RE, Hill RW, Eron LJ, Csaikl UM, Knott WB, Henderson LE, et al.
Characterization of clones of HIV-1 infected HuT 78 cells defective in gag
gene processing and of SIV clones producing large amounts of envelope
glycoprotein. J Med Primatol. 1990;19:351–66.
66. Ohkura S, Goldstone DC, Yap MW, Holden-Dye K, Taylor IA, Stoye JP. Novel
escape mutants suggest an extensive TRIM5alpha binding site spanning the
entire outer surface of the murine leukemia virus capsid protein. PLoS
Pathog. 2011;7:e1002011.
67. Ohkura S, Stoye JP. A comparison of murine leukemia viruses that escape
from human and rhesus macaque TRIM5alphas. J Virol. 2013;87:6455–68.
68. Shi J, Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1
infection depends on the stability of the incoming viral capsid. Virology.
2006;350:493–500.
69. Hatziioannou T, Cowan S, Goff SP, Bieniasz PD, Towers GJ. Restriction of
multiple divergent retroviruses by Lv1 and Ref1. EMBO J. 2003;22:385–94.
70. Besnier C, Takeuchi Y, Towers G. Restriction of lentivirus in monkeys.
Proc Natl Acad Sci U S A. 2002;99:11920–5.
71. Cowan S, Hatziioannou T, Cunningham T, Muesing MA, Gottlinger HG,
Bieniasz PD. Cellular inhibitors with Fv1-like activity restrict human and
simian immunodeficiency virus tropism. Proc Natl Acad Sci U S A.
2002;99:11914–9.
72. Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, et al. Factors
underlying spontaneous inactivation and susceptibility to neutralization of
human immunodeficiency virus. Virology. 1992;189:695–714.
73. Zhang B, Metharom P, Jullie H, Ellem KA, Cleghorn G, West MJ, et al. The
significance of controlled conditions in lentiviral vector titration and in the
use of multiplicity of infection (MOI) for predicting gene transfer events.
Genet Vaccines Ther. 2004;2:6.
74. Shi J, Zhou J, Shah VB, Aiken C, Whitby K. Small-molecule inhibition of
human immunodeficiency virus type 1 infection by virus capsid
destabilization. J Virol. 2010;85:542–9.
75. Neff T, Peterson LJ, Morris JC, Thompson J, Zhang X, Horn PA, et al. Efficient
gene transfer to hematopoietic repopulating cells using concentrated
RD114-pseudotype vectors produced by human packaging cells. Mol Ther.
2004;9:157–9.
76. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, et al. Emergence of
resistant human immunodeficiency virus type 1 in patients receiving fusion
inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896–905.
77. Adachi A, Koenig S, Gendelman HE, Daugherty D, Gattoni-Celli S, Fauci AS,
et al. Productive, persistent infection of human colorectal cell lines with
human immunodeficiency virus. J Virol. 1987;61:209–13.
78. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, et al.
Induction of AIDS in rhesus monkeys by molecularly cloned simian
immunodeficiency virus. Science. 1990;248:1109–12.
79. Kestler 3rd HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, et al.
Importance of the nef gene for maintenance of high virus loads and for
development of AIDS. Cell. 1991;65:651–62.
80. Minang JT, Trivett MT, Coren LV, Barsov EV, Piatak Jr M, Ott DE, et al.
Nef-mediated MHC class I down-regulation unmasks clonal differences in
Coren et al. Retrovirology  (2015) 12:11 Page 14 of 14virus suppression by SIV-specific CD8+ T cells independent of IFN-gamma
and CD107a responses. Virology. 2009;391:130–9.
81. Soares MA, Robertson DL, Hui H, Allan JS, Shaw GM, Hahn BH. A full-length
and replication-competent proviral clone of SIVAGM from tantalus monkeys.
Virology. 1997;228:394–9.
82. Morgenstern JP, Land H. A series of mammalian expression vectors and
characterisation of their expression of a reporter gene in stably and
transiently transfected cells. Nucleic Acids Res. 1990;18:1068.
83. Negre D, Mangeot PE, Duisit G, Blanchard S, Vidalain PO, Leissner P, et al.
Characterization of novel safe lentiviral vectors derived from simian
immunodeficiency virus (SIVmac251) that efficiently transduce mature
human dendritic cells. Gene Ther. 2000;7:1613–23.
84. Ott DE, Chertova EN, Busch LK, Coren LV, Gagliardi TD, Johnson DG.
Mutational analysis of the hydrophobic tail of the human
immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails
to package its envelope protein. J Virol. 1999;73:19–28.
85. Ott DE, Coren LV, Sowder II RC, Adams J, Nagashima K, Schubert U. Equine
infectious anemia virus and the ubiquitin-proteasome system. J Virol.
2002;76:3038–44.
86. Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, et al.
Human immunodeficiency virus type 1-induced macrophage gene
expression includes the p21 gene, a target for viral regulation. J Virol.
2005;79:4479–91.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
